Back grey_arrow_rt.gif
 
 
HIV/AIDS Pandemic Hits 30-Year Mark With Hope
 
 
  from Jules: while this article & others are now commemorating HIV/AIDS hitting the 30-year mark with having developed such heretofore unknown successful therapy so quickly against a deadly 100% fatal virus, at the same time the article below the one marking 30-years addresses older AIDS survivors dealing with premature/accelerated aging which NOW has emerged as a major concern for those individuals now aging with HIV who were infected early in the epidemic and often had low CD4s when they initiated HAART and may be suffering from what we think is that HIV itself promotes immunosenscence, premature aging of the immune system, which appears to bring on prematurely comorbidities including heart disease, kidney disease, bone disease, cognitive impairment/CNS disease and many HIV+ individuals are suffering with the affects of HCV/HIV coinfection where HIV both accelerates HCV disease for many & reduces the response to current standard of care HCV therapy- peginterferob+ribavirin; although 2 new HCV oral protease inhibitors wrre recently FDA approved & now are available, this week, in the pharmacy, their benefits for coinfected patients are limited by drug-drug interactions between HCV protease inhibitors & HIV ARTs. Vertex did study telaprevir+peg/rbv in coinfected patients and it appears in early study results to be effective but only for patients on Reaytaz/r or efavirenz, + nukes. Because of the drug-drug interactions other HIV protease inhibitors could not be taken with telaprevir, and Merck is planning their drug-drug interaction studies now. Some doctors who have coinfected patients who need treatment right away and who are on these other protease inhibitors/ARTs are considering to use experiment dosing of HIV protease inhibitors in combination with telaprevir.
 
HIV/AIDS Pandemic Hits 30-Year Mark With Hope

 
By Michael Smith, North American Correspondent, MedPage Today
Published: May 29, 2011
 
Thirty years ago this week, researchers and clinicians were putting the finishing touches on an article intended for the June 5 issue of Morbidity and Mortality Weekly Report.
 
Titled "Pneumocystis Pneumonia -- - Los Angeles," the seven-paragraph report was the first dispatch from the front lines of humanity's remarkable war against a previously unknown virus.
 
The war began with a complete lack of good news - the new disease was almost 100% fatal, often within weeks or months. No one knew what caused it or how it was transmitted. No one knew how to prevent it, to treat it, and certainly not how to cure it.
 
Thirty years on, the HIV/AIDS pandemic is still raging, but the news from the front is more and more positive.
 
Infection can be prevented, if people have the will. The virus is increasingly well understood, as is the immune system and the host-pathogen interaction. The disease can be treated, although a cure remains out of reach.
 
Perhaps most important - while many people still die because of the virus - HIV is no longer a death sentence.
 
In the Beginning
 
Anthony Fauci, MD, now the head of the National Institute of Allergy and Infectious Diseases, was a 10-year veteran of the NIH at the time, with a lab studying the immune system and host-pathogen interactions.
 
"I remember quite clearly," he told MedPage Today, as he recalled sitting in his office, leafing through that week's MMWR, and coming across the report from Los Angeles.
 
He knew Pneumocystis pneumonia - usually abbreviated PCP - as a disease usually seen in people with compromised immune systems, often cancer patients undergoing chemotherapy.
 
But the MMWR report struck him as a curiosity, until a month later when a second report from the CDC hit his desk.
 
Now there were 26 patients, not five.
 
They were from Los Angeles, San Francisco, and New York. They were all gay and previously healthy. And some of them had Kaposi's sarcoma, another disease usually seen in people with compromised immune systems.
 
"At that point I just got goose pimples," Fauci said. "I said, 'Oh my goodness, we're dealing with something really new here.'"
 
Despite the horrified reaction of friends and mentors, he made the immediate decision to turn his attention to this new "curiosity of a disease."
 
It's a story repeated again and again by those who have been involved in the pandemic.
 
Carol Hamilton, MD, of Research Triangle Park, N.C., is a senior scientist with FHI, a research professor at Duke University, and a clinician with decades of experience in treating HIV. She's also a member of the Infectious Diseases Society of America's Center for Global Health Policy and Advocacy.
 
But in 1981, she was working in public health in Utah, before going to medical school. And even there, she and colleagues were seeing strange illnesses among gay men - lots of syphilis and gonorrhea, yes, but also a "very worrisome" infection that had no known cause.
 
"It was frightening, honestly," she told MedPage Today.
 
She had intended to practice obstetrics, but in medical school she found internal medicine and infectious disease - especially HIV - much more compelling.
 
"The HIV epidemic seemed to be the important issue of the age," she said.
 
Heady Times
 
The early years were both "exciting and fascinating" in a scientific sense, she said, but also unspeakably tragic in a personal and clinical sense.
 
"Remember, all of our patients died - 100%," Hamilton said. All a doctor could do was try to help them die with a maximum of dignity and a minimum of suffering.
 
Looking back from 2011, it seems as if progress was relatively swift. After the initial report, it was only three years until, in 1984, the virus was isolated. A year later, the first diagnostic test was licensed and in 1987 AZT, the first anti-HIV drug, was approved.
 
But at the time, it seemed horribly slow, according to Sten Vermund, MD, PhD, a pediatrician at Vanderbilt University School of Medicine in Nashville, Tenn., and also a member of the IDSA Center for Global Health Policy and Advocacy.
 
In the 1980s, when Vermund was working in New York, "things looked like they were progressing very slowly because of the death that just permeated our city," he told MedPage Today.
 
"HIV washed over us like a slow tsunami," he said.
 
There were treatments for the various opportunistic infections that were killing HIV-positive people, he said, but the drugs "just didn't get a clinical response."
 
Now, of course, we know why - HIV had knocked out the immune system cells that are the key allies of any drug therapy.
 
Then, in 1996, doctors could suddenly offer long-term hope, with the advent of highly active anti-retroviral therapy, or HAART. Drug "cocktails" could now keep people with HIV from progressing to AIDS and dying.
 
The End of the Beginning
 
To paraphrase Winston Churchill, the battle against HIV/AIDS was not at an end, nor even at the beginning of the end. But it was, perhaps, at the end of the beginning.
 
For people like Carol Hamilton, it was "miraculous." From helping people to die - she once said she felt like a "midwife of death" - she could now help them live.
 
Although the early years of the pandemic were terrifying and frustrating for those on the front lines, it's fair to say that scientific progress over the past 15 years has been constant.
 
Indeed, Fauci goes so far as to call it "breath-taking" as dozens of new drugs were developed and several new methods of prevention were discovered and shown to work.
 
Indeed, within the past month, a landmark study has shown that treating people with HIV can reduce the chance they'll transmit the virus by 96%.
 
Michael Saag, MD, of the University of Alabama Birmingham, says that finding puts an additional value on treatment.
 
"Not only can we treat people and keep them alive for a normal lifetime," he told MedPage Today, but as an "added bonus" the treated people will be highly unlikely to transmit HIV.
 
"To me, treatment is prevention," he said.
 
Still Daunting
 
But getting advances to all the people who need them remains a challenge. There are still 2.6 million new infections a year around the world and 1.8 million deaths from HIV/AIDS.
 
Even in the U.S., there are 50,000 new infections each year, and more than a million people live with HIV, with an estimated 25% of those completely unaware they have the virus.
 
Despite the availability of treatment, there are even deaths in the U.S. and other advanced countries, Hamilton noted - usually those who can't or won't for some reason take their medications.
 
What's needed now is a program of research that will overcome barriers to care and treatment, Vermund argues, as well as a renewed emphasis on preventing its transmission.
 
The past 15 years have seen a steady increase in the number of prevention methods available, Vermund noted. To abstinence, being faithful, and condoms - the so-called ABC of prevention - we can now add male circumcision, microbicides, and early HIV treatment.
 
Combination therapy "knocked the socks off" HIV on an individual basis, he said, and what's needed now is research into combination prevention strategies.
 
"Sadly," he said, "we are trying to do this in an era of global fiscal restraint" where international funders "no longer have the fire in the belly" needed to undertake the struggle.
 
Saag, a former chair of the HIV Medicine Association, said scientifically the past three decades have been "stunning" and unique in the history of medicine.
 
"In the 30 years since the first description, we've taken something that was previously totally unknown as a disease entity and converted it into a chronic manageable condition," he said.
 
As long as HIV-positive people are found, cared for, treated, and adhere to their therapy, he said, they can look forward to an essentially normal lifetime.
 
But again, those conditions have to be met and all too often they aren't. Saag said what's needed is a "new era of translational medicine - not just bench to bedside but also bedside to community."
 
The Final Lesson
 
In the last analysis, it's very possible we now have the tools to control HIV around the world, even if we don't know yet just how to use them best and even if we may not have the will and the cash to find out.
 
But, Hamilton said, it's unlikely that HIV is the last unknown pathogen lying in wait for humanity.
 
"Will we have learned? Instead of it taking 15 years (to get effective treatments), will we take seven years?"
 
"I would say yes, we have learned."
 
----------------------------------
 
Older AIDS survivors face new challenges
 
By Hannah Dreier, Agence France-Presse
Posted at 05/30/2011 10:14 AM | Updated as of 05/30/2011 2:55 PM
 
SAN FRANCISCO, United States - AIDS nearly killed Lou Grosso 3 decades ago, but that didn't prepare him for the latest news from his doctor: he has heart disease.
 
Like many older HIV carriers facing problems -- including financial -- they never expected to live long enough to confront, Grosso, 57, also suffers from aching joints, memory loss and nerve pain.
 
Of the 14 pills he takes each day, only 3 are designed to treat HIV.
 
Dr. Brad Hare, his specialist at San Francisco General Hospital, keeps track of it all, but Grosso is still worried.
 
"I've often said to my doctors, 'You're so worried about the AIDS but I'm gonna drop over from a heart attack'," Grosso said. "It bothers me; I'm having a good life and don't want it to be cut short because my body thinks I'm 80."
 
While many have turned their attention -- and money -- to fighting the epidemic in Africa, experts here are increasingly troubled by a new kind of AIDS crisis.
 
Some 15 years into the era of protease inhibitors and drug cocktails, the first large group of AIDS patients to go through the aging process is facing a host of unexpected medical conditions, not to mention psychological and financial challenges they never thought they would live to see.
 
Grosso, who programmed some of the first personal software in the 80s, is amazed that he has survived long enough to learn how to build websites.
 
But he also worries that his mind isn't as sharp as it once was. He finds himself arguing with colleagues about whether topics were covered in meetings, for example.
 
"I'll just have no memory of it," he said.
 
A recent study found that52% of HIV positive Americans suffer from some type of cognitive impairment. Only 10% of people in the general population, by contrast, experience such problems, according to the CNS HIV Antiretroviral Therapy Effects Research study.
 
HIV patients aged 55 and older are also 3 times as likely as non-infected 70 year-olds to suffer from a chronic health problem, according to the American Academy of HIV Medicine. Common illnesses include hypertension, diabetes, osteoporosis and cancer.

 
In the early days of the epidemic, patients in their 20s were dying in overwhelming numbers in Dr. Hare's HIV/AIDS ward.
 
Today, more than a quarter of HIV patients are 50 years or older, according to the US Centers for Disease Control, and the average age in Hare's 3,000 patient clinic is 47.
 
"The problems people with HIV face are really changing," Hare said.
 
"I've heard patients say that it just wears them down. You've been dealing with HIV for 30 years and you finally have that under control, and now you're facing a new raft of medical problems. It seems unfair."

 
Experts are just starting to tease out which of these illnesses are caused by the virus, which are drug side-effects and which are just natural signs of aging.
 
Until recently, there were too few people aging with HIV to study.
 
The challenges posed by the greying of AIDS are not only clinical.
 
Experts also worry about patients like Vicki Davidson, who was planning to abandon her HIV treatment during a particularly lonely period this winter.
 
Davidson, 64, contracted HIV in 1986 from a blood transfusion after she was caught in a fire.
 
She underwent 2 hip replacements at the age of 50 and suffers from severe fatigue.
 
But what really gets her down is the social isolation -- the days spent at home, the difficulty of connecting with new people.
 
Like many long-term survivors, Davidson worries that it might seem indecent to complain about the consequences of aging with HIV when for so many years, survival itself was at stake.
 
"I don't want people to think, 'there's a whiner'," she said, "so I act like it's no big thing. But in my quiet moments, I think it would be nice to have a partner."
 
Long-term HIV patients are almost 13 times more likely to suffer from depression than other Americans, according to a 2006 study from the AIDS Community Research Initiative of America.
 
Davidson said she is feeling more hopeful of late, though a question about what brings her happiness draws only a long pause and then laughter.
 
Older AIDS patients are also more likely to be unemployed or short on savings than their healthy counterparts, according to a study from the Terrence Higgins Trust.
 
Homer Hobi, 65, recently went back to work as a realtor at an age when many of his friends are retiring.
 
In the 90s, he gave his home, business and a chunk of money to his ex-wife, despite the protestations of his divorce lawyer.
 
"There was no doctor that I talked to in '96, '97 that thought I'd be alive in 10 years," he explained.
 
Though stomach issues sometimes keep him homebound, Hobi said he is glad to be back at work, if only for the social outlet it affords him.
 
Lou Grosso has also had his share of financial difficulties -- he even spent some time on the street.
 
Now he lives in subsidized housing for people with AIDS and spends his time coding, participating in clinical studies and volunteering with younger patients.
 
Grosso, who loves science fiction books because they depict worlds where anything is possible, sees himself as a guinea pig in the service of generations to come.
 
"Why am I still here?" he said. "There's a reason why I'm still alive, and I want someone to find out why that is."
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org